Ong, Mian-Li
,
Youngstrom, Eric A.
Chua, Jesselyn Jia-Xin
Halverson, Tate F.
Horwitz, Sarah M.
Storfer-Isser, Amy
Frazier, Thomas W.
Fristad, Mary A.
Arnold, L. Eugene
Phillips, Mary L.
Birmaher, Boris
Kowatch, Robert A.
Findling, Robert L.
Funding for this research was provided by:
National Institute of Mental Health (5R01MH073967)
Article History
First Online: 1 July 2016
Compliance with Ethical Standards
:
: This study was funded in part by National Institutes of Health (grant number NIH R01 MH073967; PI: R.L. Findling).
: Mian-Li Ong declares that he has no conflict of interest. Eric Youngstrom has consulted with Pearson, Western Psychological Services, Johnson & Johnson, Lundbeck and Otsuka about psychological assessment. Jesselyn Jia-Xin Chua declares that she has no conflict of interest. Tate Halverson declares that she has no conflict of interest. Sarah Horwitz declares that she has no conflict of interest. Amy Storfer-Isser declares that she has no conflict of interest. Thomas Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, National Institutes of Health, and the Brain and Behavior Research Foundation. Mary Fristad receives royalties from American Psychiatric Press, CFPSI and Guilford Press and honoraria from American Occupational Therapy Association and Physicians’ Post-Graduate Press. Eugene Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, and YoungLiving (as well as NIH and Autism Speaks) and has consulted with or been on advisory boards for Arbor, Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, Tris Pharma, and Waypoint and received travel support from Noven. Mary Phillips is a consultant for Roche Pharmaceuticals. Robert Kowatch declares that he has no conflict of interest. Robert Findling receives or has received research support, acted as a consultant and/or served on a speaker’s bureau for Alcobra, American Academy of Child & Adolescent Psychiatry, American Physician Institute, American Psychiatric Press, AstraZeneca, Bracket, Bristol-Myers Squibb, CogCubed, Cognition Group, Coronado Biosciences, Dana Foundation, Elsevier, Forest, GlaxoSmithKline, Guilford Press, Johns Hopkins University Press, Johnson and Johnson, Jubilant Clinsys, KemPharm, Lilly, Lundbeck, Merck, NIH, Neurim, Novartis, Noven, Otsuka, Oxford University Press, Pfizer, Physicians Postgraduate Press, Purdue, Rhodes Pharmaceuticals, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Transcept Pharmaceuticals, Validus, and WebMD.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.